Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H22N4 |
Molecular Weight | 282.3834 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=NC(CC2=CC=CC=C2)=NC3=C1CCNC[C@@H]3C
InChI
InChIKey=IHHALLDEDARSAL-LBPRGKRZSA-N
InChI=1S/C17H22N4/c1-12-11-19-9-8-14-16(12)20-15(21-17(14)18-2)10-13-6-4-3-5-7-13/h3-7,12,19H,8-11H2,1-2H3,(H,18,20,21)/t12-/m0/s1
Molecular Formula | C17H22N4 |
Molecular Weight | 282.3834 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24878222
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24878222
PF-04479745 (PF-4479745) is a selective serotonin 5HT2C agonist. PF-4479745 displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5-HT2B in relevant tissue-based assay systems.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24878222
Curator's Comment: shown in in vivo canine PUP model of SUI
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24878222 |
10.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24878222
Curator's Comment: PF-04479745 was administered as continuous infusions in appropriate vehicle, doses and
infusion rate were calculated based on previously obtained pharmacokinetic (IV bolus) data in
order to achieve plasma concentrations in the region of between 3 and 10 times the in vitro EC50
against the human 5-HT2c receptor from cell-based assays.
Rats: Following single intravenous
administration of PF-04479745 to rat, systemic clearance was
high (104 mL min−1 kg−1, approximately equal to hepatic blood
flow).
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24878222
Curator's Comment: Agonist activity at recombinant human 5-HT2C receptor expressed in CHO K1 cells assessed as calcium mobilization by FLIPR assay
PF-04479745 exhibited agonist activity at recombinant human 5-HT2C receptor with EC50 10 nM
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:08:23 GMT 2023
by
admin
on
Sat Dec 16 18:08:23 GMT 2023
|
Record UNII |
73HBY5P486
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID701336532
Created by
admin on Sat Dec 16 18:08:23 GMT 2023 , Edited by admin on Sat Dec 16 18:08:23 GMT 2023
|
PRIMARY | |||
|
1065110-43-1
Created by
admin on Sat Dec 16 18:08:23 GMT 2023 , Edited by admin on Sat Dec 16 18:08:23 GMT 2023
|
PRIMARY | |||
|
PF-04479745
Created by
admin on Sat Dec 16 18:08:23 GMT 2023 , Edited by admin on Sat Dec 16 18:08:23 GMT 2023
|
PRIMARY | |||
|
90644511
Created by
admin on Sat Dec 16 18:08:23 GMT 2023 , Edited by admin on Sat Dec 16 18:08:23 GMT 2023
|
PRIMARY | |||
|
73HBY5P486
Created by
admin on Sat Dec 16 18:08:23 GMT 2023 , Edited by admin on Sat Dec 16 18:08:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|